ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The European Commission says it will intensify its scrutiny of anticompetitive practices in the pharmaceutical industry, particularly practices that hinder the introduction of low-cost generic drugs. An inquiry launched by the administrative arm of the European Union more than a year ago (C&EN Online Latest News, Jan. 17, 2008) turned up significant delays in the introduction of generics after original makers' patents expired. Neelie Kroes, commissioner for competition policy, says that the first antitrust investigations are already under way.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X